thrombotic thrombocytopenic purpura

thrombotic thrombocytopenic purpura
Name	Thrombotic thrombocytopenic purpura

thrombotic thrombocytopenic purpura is a rare, life-threatening hematologic disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia, historically described in case series from the early 20th century and studied in clinical trials at institutions such as Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. It was subject of classic reports by clinicians in the era of Willis A. R., and modern management evolved alongside protocols developed at National Institutes of Health, Food and Drug Administration, and through collaborations including World Health Organization, American Society of Hematology, and research centers like Massachusetts General Hospital. Diagnostic and therapeutic approaches integrate findings validated in cohorts from Harvard Medical School, Oxford University Hospitals, and multicenter studies involving centers such as Karolinska University Hospital and University of Toronto.

Signs and symptoms

Patients typically present with a pentad historically taught in texts from Guy's Hospital, St Thomas' Hospital, and case series collated by Royal College of Physicians scholars: fever, neurologic deficits, renal impairment, thrombocytopenia, and microangiopathic hemolytic anemia, described in reports from Cambridge University Hospitals, King's College Hospital, and Beth Israel Deaconess Medical Center. Neurologic manifestations range from confusion and headache to focal deficits and seizures; such presentations are documented in neurologic literature from Mayo Clinic and stroke registries at University College London Hospitals. Mucocutaneous bleeding and petechiae are commonly noted in emergency department series from Mount Sinai Health System and trauma registries at University of California, San Francisco Medical Center. Renal involvement varies from mild azotemia to acute kidney injury, as reported in nephrology case reports from Cleveland Clinic and Vanderbilt University Medical Center.

Pathophysiology

The central mechanism involves severe deficiency of the metalloprotease ADAMTS13, first characterized in molecular studies at University of California, San Diego and National Institutes of Health, leading to accumulation of ultra-large von Willebrand factor multimers and platelet-rich thrombi in small vessels, a process explored in basic research at Cold Spring Harbor Laboratory and Max Planck Institute. Autoimmune forms are associated with anti-ADAMTS13 autoantibodies described in immunology reports from Scripps Research, Fred Hutchinson Cancer Center, and studies affiliated with Stanford University School of Medicine, whereas hereditary forms (Upshaw–Schulman syndrome) link to mutations cataloged in genetic databases curated by European Bioinformatics Institute and Broad Institute. Endothelial activation and complement pathway interactions have been investigated in translational studies at University of Pennsylvania Perelman School of Medicine and Karolinska Institute, and associations with triggers such as pregnancy and HIV infection have been reported in obstetrics and infectious disease series from Johns Hopkins Hospital and Centers for Disease Control and Prevention.

Diagnosis

Diagnosis relies on clinical judgment supported by laboratory assays developed and standardized in reference laboratories at Mayo Clinic and Quest Diagnostics, including ADAMTS13 activity measurement, inhibitor testing, and peripheral blood smear examination showing schistocytes, as validated in hematology protocols from American Society of Hematology and consensus statements from European Hematology Association. Differential diagnoses include hemolytic uremic syndrome and disseminated intravascular coagulation, distinguished in reviews from University of Oxford and Imperial College London, and management often follows algorithms promulgated by guideline committees at National Institute for Health and Care Excellence and Canadian Blood Services. Rapid utilitarian scoring systems used in emergency departments at Massachusetts General Hospital and Mount Sinai Health System help prioritize urgent interventions.

Treatment and management

First-line therapy is therapeutic plasma exchange, a modality refined in transfusion medicine programs at Mayo Clinic and implemented widely in centers such as Cleveland Clinic and UCLA Medical Center, often combined with immunosuppression (corticosteroids) as practiced in protocols from Mount Sinai Hospital and Brigham and Women's Hospital. Rituximab and caplacizumab have been employed based on trials and regulatory approvals involving collaborators at National Institutes of Health, European Medicines Agency, and pharmaceutical partners; adjunctive care includes supportive transfusion and renal replacement performed in nephrology units at Johns Hopkins Hospital and Toronto General Hospital. Genetic counseling for hereditary cases is provided by clinics affiliated with Genentech-supported programs and university centers including Columbia University Irving Medical Center, and pregnancy-associated management has been coordinated through maternal-fetal medicine services at Cleveland Clinic and University of California, San Francisco.

Prognosis and complications

Without prompt treatment, historical series from Johns Hopkins Hospital and Mayo Clinic reported high mortality, whereas contemporary outcomes from registries at European Group for Blood and Marrow Transplantation and American Society of Hematology show markedly improved survival after plasma exchange and targeted agents; long-term complications include chronic kidney disease, neurocognitive impairment, and relapse, documented in follow-up studies from Massachusetts General Hospital and Karolinska University Hospital. Relapse risk and healthcare utilization have been analyzed in population studies from Centers for Disease Control and Prevention and national registries in Sweden and Canada.

Epidemiology and risk factors

Incidence estimates derive from epidemiologic surveillance in regions served by Centers for Disease Control and Prevention, national registries in France and United Kingdom, and multicenter cohorts at University of Toronto and Mayo Clinic, indicating a rare disease with incidence roughly 2–6 per million per year and higher burden among adults in urban centers such as New York City and Chicago. Risk factors include female sex and certain exposures such as medications and infections reported in pharmacovigilance databases at Food and Drug Administration and infectious disease case series from World Health Organization, with hereditary mutations concentrated in populations studied at Broad Institute and Karolinska Institute.

Category:Hematology